C. Goodwin

发表

Drugging an undruggable pocket on KRAS

M. Koegl, S. Fesik, A. Waterson, 2019, Proceedings of the National Academy of Sciences.

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.

E. Olejniczak, S. Fesik, O. Rossanese, 2016, Journal of medicinal chemistry.

Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Nicole M. Baker, E. Petricoin, D. Esposito, 2019, Cancer discovery.

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

James M. McFarland, Laura E. Herring, Yingyao Zhou, 2020, Cell reports.

Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.

E. Petricoin, C. Der, K. Wood, 2022, Molecular cancer therapeutics.

Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors.

E. Petricoin, K. Wennerberg, C. Der, 2021, Cancer research.

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.

C. Der, A. Cox, Priya S. Hibshman, 2022, Advances in cancer research.

Functional and biological heterogeneity of KRASQ61 mutations

E. Petricoin, C. Der, N. Rashid, 2022, Science Signaling.

Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers

M. Koegl, S. Fesik, A. Waterson, 2020, Proceedings of the National Academy of Sciences.

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

E. Petricoin, C. Der, C. Kuo, 2021, Cell reports.

Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer

E. Olejniczak, S. Fesik, O. Rossanese, 2015, Cell Death and Differentiation.

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Laura E. Herring, E. Petricoin, K. Wennerberg, 2020, Cell reports.

Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen

E. Briem, C. Der, G. Maelandsmo, 2021, Molecular oncology.

MOLECULAR CANCER THERAPEUTICS | TARGETING DRUG RESISTANCE Vertical Inhibition of the RAF–MEK–ERKCascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS Mutant Rhabdomyosarcoma

P. Houghton, M. Yohe, Yidong Chen, 2021 .

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.

E. Petricoin, C. Der, P. Roberts, 2022, Cancer research.

Binding energies for alkane molecules on a carbon surface from gas-solid chromatography and molecular mechanics.

Christina E. Wells, T. Rybolt, H. E. Thomas, 2008, Journal of colloid and interface science.

Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma

P. Houghton, M. Yohe, Yidong Chen, 2021, Molecular Cancer Therapeutics.

Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors

A. Letai, E. Olejniczak, S. Fesik, 2017, FEBS letters.